Recordati, Moderna Partner on mRNA Therapy for Rare Metabolic Disease
Recordati has entered into a global collaboration and licensing agreement with Moderna to develop and commercialize mRNA-3927, an investigational mRNA-based therapy for the treatment of…
Read More...
Read More...
